Literature DB >> 21783234

Systemic exposure to fluticasone MDI delivered through antistatic chambers.

Mai K Elmallah, Yasmeen Khan, Guenther Hochhaus, Jonathan J Shuster, Leslie Hendeles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21783234      PMCID： PMC3811012          DOI： 10.1016/j.jaci.2011.06.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  10 in total

1.  A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma.

Authors:  S Krishnaswami; H Möllmann; H Derendorf; G Hochhaus
Journal:  J Pharm Biomed Anal       Date:  2000-02       Impact factor: 3.935

2.  Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler.

Authors:  O J Dempsey; A M Wilson; W J Coutie; B J Lipworth
Journal:  Chest       Date:  1999-10       Impact factor: 9.410

3.  Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children.

Authors:  B J Lipworth; D J Clark; L C McFarlane
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

4.  Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate.

Authors:  Nemr Eid; Ronald Morton; Bradley Olds; Pamela Clark; Shahid Sheikh; Stephen Looney
Journal:  Pediatrics       Date:  2002-02       Impact factor: 7.124

5.  An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy.

Authors:  S Krishnaswami; G Hochhaus; H Derendorf
Journal:  AAPS PharmSci       Date:  2000

6.  A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.

Authors:  B Meibohm; G Hochhaus; H Möllmann; J Barth; M Wagner; M Krieg; R Stöckmann; H Derendorf
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

7.  A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids.

Authors:  Harold S Nelson; Wes Stricker; Thomas B Casale; Hershel Raff; Jon A Fourré; David C Aron; Kenneth B Newman
Journal:  J Clin Pharmacol       Date:  2002-03       Impact factor: 3.126

8.  Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma.

Authors:  Jian Xu; Rüdiger Nave; Gezim Lahu; Eric Derom; Hartmut Derendorf
Journal:  J Clin Pharmacol       Date:  2010-02-11       Impact factor: 3.126

9.  Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler.

Authors:  Arun Nair; Daniel Menzies; Martyn Barnes; Patricia Burns; Lesley McFarlane; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

10.  In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler.

Authors:  Arun Nair; Daniel Menzies; Pippa Hopkinson; Lesley McFarlane; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2009-02-09       Impact factor: 4.335
  10 in total
  3 in total

Review 1.  Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?

Authors:  Hengameh H Raissy; H William Kelly
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

2.  The Effect of Spacer Morphology on the Aerosolization Performance of Metered-Dose Inhalers.

Authors:  Sepideh Momeni; Ali Nokhodchi; Saeed Ghanbarzadeh; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2016-06-30

3.  Inhaled corticosteroids in lung diseases.

Authors:  Hengameh H Raissy; H William Kelly; Michelle Harkins; Stanley J Szefler
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.